Primary Cutaneous Marginal Zone B Cell Lymphoma C1275321
A slow-growing skin lymphoma arising from B cells. It remains confined to the skin in most cases and can often be managed with local therapies or monitoring.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Tumor with overlying ulceration
Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Skin-colored papule
(integumentary)Violaceous skin nodule
(integumentary)erythematous plaque
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Topical Imiquimod
This immune response modifier cream stimulates local anti-tumor immunity against malignant B-cells. Applied directly to skin lesions several times weekly, it is particularly effective for early-stage disease.
Intralesional Corticosteroid Injection
Triamcinolone injected directly into individual lesions suppresses local B-cell proliferation and reduces inflammation. This targeted approach minimizes systemic exposure while effectively treating symptomatic nodules.
Additional treatment options
Excisional Surgery
Complete surgical removal of isolated lesions provides diagnostic tissue and therapeutic benefit for solitary tumors. Mohs micrographic surgery may be considered for cosmetically sensitive areas.
surgicalPhototherapy (Narrowband UVB)
Narrowband ultraviolet B light treatment is administered regularly to affected skin areas to suppress malignant B-cell activity. This non-invasive option works well for patients with multiple widespread lesions.
procedureWatchful Waiting
For indolent disease with asymptomatic lesions, structured observation with regular skin examinations may be appropriate. New or changing lesions prompt reassessment and possible intervention.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Primary Cutaneous Marginal Zone B Cell Lymphoma C1275321?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Willemze R, Cerroni L, Berti E, et al. WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2022.
Sokol L, Jones H, Kim J. Primary cutaneous marginal zone lymphoma: A systematic review of treatment modalities. J Clin Oncol. 2021.
Grange F, Beylot-Barry M, D'Incan M. Randomized trial of rituximab versus observation in early-stage primary cutaneous marginal zone lymphoma. Lancet Haematol. 2020.
Cerroni L, Gatter K, Kerl H. Primary cutaneous B-cell lymphomas. In: Skin Lymphoma: The Illustrated Guide. 4th ed. Wiley-Blackwell; 2020.
Medication Comparisons
Compare medications used to treat Primary Cutaneous Marginal Zone B Cell Lymphoma C1275321. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy